Special Issue "Clinical Pharmacology of Anticancer Agents"
A special issue of International Journal of Environmental Research and Public Health (ISSN 1660-4601). This special issue belongs to the section "Global Health".
Deadline for manuscript submissions: closed (15 June 2023) | Viewed by 2342
Special Issue Editors
Interests: clinical pharmacology; medical oncology; clinical trials; breast cancer; heath-related quality of life; cardiotoxicity; adverse events
2. Department of Anatomy, Jagiellonian University Medical College, 31-008 Kraków, Poland
Interests: clinical oncology; melanoma; breast cancer; cancer immunotherapy; thrombosis; clinical anatomy
Special Issue Information
Dear Colleagues,
Cancer remains one of the leading causes of death and, thus, one of the main public health issues. In recent years, there has been great acceleration in number of new anti-cancer compounds in preclinical and clinical studies. Traditional cytotoxic drugs are now supported or replaced by a growing number of molecular targeting agents, gene therapies, cellular therapies, radio-labelled drugs, antibody–drug conjugates, and checkpoint inhibitors.
Clinical pharmacology explores the relationship between medicines and humans on the molecular, cellular, and organ level. It is a translational discipline accompanying the drug from its discovery, through pre-clinical and clinical studies until its introduction to the market. Clinical pharmacology supports the idea of precision medicine in oncology in order to maximize the anti-cancer therapy efficacy and safety.
Our Special Issue welcomes both original studies and review articles focusing on the clinical pharmacology of anticancer agents to provide a better understanding of the molecular background of innovative cancer therapies, discuss the implementation of novel compounds into clinical practice, and share advances in the efficacy and safety of their administration. Papers regarding pharmacokinetics, pharmacodynamics, or pharmacogenomics but also presenting peculiar adverse drug reactions, drug interactions, or real-world efficacy data are welcomed.
Dr. Miroslawa Puskulluoglu
Dr. Renata Pacholczak-Madej
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Environmental Research and Public Health is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- clinical pharmacology
- pharmacokinetics
- pharmacodynamics
- pharmacogenomics
- anticancer agents
- targeted treatment
- immunotherapy
- side effects
- drug interactions
- molecular mechanisms
